Maxadilan Reduces Atherosclerosis in Mice
Author Information
Author(s): Mey Lilli, Bonaterra Gabriel A., Hoffmann Joy, Schwarzbach Hans, Schwarz Anja, Eiden Lee E., Weihe Eberhard, Kinscherf Ralf
Primary Institution: Philipps-University of Marburg
Hypothesis
Does the PAC1 receptor agonist Maxadilan affect atherogenesis in ApoE−/− mice?
Conclusion
Maxadilan treatment significantly reduces atherosclerotic lesions and lumen stenosis in hypercholesterolemic ApoE−/− mice.
Supporting Evidence
- Maxadilan-treated mice showed a lower percentage of atherosclerotic plaques compared to Sham and M65-treated mice.
- Maxadilan significantly inhibited lumen stenosis in both standard chow and cholesterol-enriched diet groups.
- Despite increased cholesterol levels, Maxadilan treatment maintained similar lumen stenosis compared to Sham.
- Maxadilan reduced TNF-α and IL-1β areas in plaques, indicating anti-inflammatory effects.
Takeaway
Maxadilan is a special medicine that helps mice with heart problems by making their blood vessels healthier.
Methodology
Adult male ApoE−/− mice were treated with Maxadilan or M65 and fed either a cholesterol-enriched diet or standard chow, with effects on atherosclerotic plaques and lumen stenosis analyzed.
Potential Biases
Potential bias in the selection of treatment groups and the interpretation of results.
Limitations
The study was conducted only in male mice, which may limit the generalizability of the findings.
Participant Demographics
Adult male ApoE−/− mice.
Statistical Information
P-Value
p = 0.011
Statistical Significance
p ≤ 0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website